

Press Release  
Västra Frölunda, Sweden, February 16, 2007

## **Artimplant Year End Report 2006 Conference Call**

---

**CEO Hans Rosén and CFO Lars-Johan Cederbrant present Year End Report 2006.**

The presentation will be in Swedish.

Date: Tuesday, February 20  
Time 15.00 CET (GMT+1)

Dial in number:  
Sweden: + 46 (0) 850 520 270  
USA: +1 718 354 1226

A live broadcast of the conference call will be available on Artimplant's website [www.artimplant.com](http://www.artimplant.com)

Please note that Artimplant's Year End Report 2006 will be distributed with a press release on February 20, 2006 approximately 14.00 Central European Time (GMT+1).

---

### **For additional information, please contact:**

Lars-Johan Cederbrant, CFO, phone +46 (0)31 -746 56 54, +46 (0)703 01 68 54,  
[lars-johan.cederbrant@artimplant.com](mailto:lars-johan.cederbrant@artimplant.com)

Web site: [www.artimplant.com](http://www.artimplant.com)

### **About Artimplant**

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life.

Our products, made from Artelon<sup>®</sup>, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder injuries and other soft tissue injuries as well as dental applications.

Our motto is "Help the body to heal".

Artimplant is a public company listed on the Nordic Exchange.

### **Forward-looking statements**

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.